ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy

被引：2
|
作者：
Bossi, A. [1 ]
Dearnaley, D. [2 ,3 ]
McKenzie, M. [4 ]
Baskin-Bey, E. [5 ]
Tyler, R. [5 ]
Tombal, B. [6 ]
Freedland, S. J. [7 ]
Roach, M., III [8 ]
Widmark, A. [9 ]
Dicker, A. P. [10 ]
Wiegel, T. [11 ]
Shore, N. [12 ]
Smith, M. [13 ,14 ]
Yu, M. [5 ]
Kheoh, T. [15 ]
Thomas, S. [16 ]
Sandler, H. M. [17 ]
机构：
[1] Inst Gustave Roussy, Radiat Oncol, Villejuif, France
[2] Inst Canc Res, Acad Radiotherapy, London, England
[3] Royal Marsden Hosp, London, England
[4] British Columbia Canc Agcy, Med Oncol, Vancouver, BC, Canada
[5] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA
[6] Clin Univ St Luc, Urol, Brussels, Belgium
[7] Cedars Sinai Med Ctr, Surg, Los Angeles, CA 90048 USA
[8] Univ Calif San Francisco, Radiat Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[9] Umea Univ, Radiat Sci, Umea, Sweden
[10] Thomas Jefferson Univ, Radiat Oncol, Philadelphia, PA 19107 USA
[11] Ulm Med Univ, Radiat Oncol, Ulm, Germany
[12] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA
[13] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA
[14] Harvard Med Sch, Boston, MA USA
[15] Janssen Res & Dev, Clin Biostat, San Diego, CA USA
[16] Janssen Pharmaceut, Oncol Translat Res, Spring House, PA USA
[17] Cedars Sinai Med Ctr, Radiat Oncol, Los Angeles, CA 90048 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw372.52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
769TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Initial patient-reported outcomes of neoadjuvant apalutamide (ARN509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial - a phase II trial
    Yang, X.
    Aslim, E. J.
    Chong, T. W.
    Yuen, J.
    Tay, K. J.
    Ho, H.
    Lee, L. S.
    BJU INTERNATIONAL, 2019, 123 : 38 - 38
  • [22] Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial
    Blanchard, Pierre
    Faivre, Laura
    Lesaunier, Francois
    Salem, Naji
    Mesgouez-Nebout, Nathalie
    Deniau-Alexandre, Elisabeth
    Rolland, Frederic
    Ferrero, Jean-Marc
    Houede, Nadine
    Mourey, Loic
    Theodore, Christine
    Krakowski, Ivan
    Berdah, Jean-Francois
    Baciuchka, Marjorie
    Laguerre, Brigitte
    Davin, Jean-Louis
    Habibian, Muriel
    Culine, Stephane
    Laplanche, Agnes
    Fizazi, Karim
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (01): : 85 - 92
  • [23] Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
    Warde, Padraig
    Mason, Malcolm
    Ding, Keyue
    Kirkbride, Peter
    Brundage, Michael
    Cowan, Richard
    Gospodarowicz, Mary
    Sanders, Karen
    Kostashuk, Edmund
    Swanson, Greg
    Barber, Jim
    Hiltz, Andrea
    Parmar, Mahesh K. B.
    Sathya, Jinka
    Anderson, John
    Hayter, Charles
    Hetherington, John
    Sydes, Matthew R.
    Parulekar, Wendy
    LANCET, 2011, 378 (9809): : 2104 - 2111
  • [24] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Vadim S. Koshkin
    Maria C. Mir
    Pedro Barata
    Anita Gul
    Ruby Gupta
    Andrew J. Stephenson
    Jihad Kaouk
    Ryan Berglund
    Cristina Magi-Galluzzi
    Eric A. Klein
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2019, 37 : 559 - 566
  • [25] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Koshkin, Vadim S.
    Mir, Maria C.
    Barata, Pedro
    Gul, Anita
    Gupta, Ruby
    Stephenson, Andrew J.
    Kaouk, Jihad
    Berglund, Ryan
    Magi-Galluzzi, Cristina
    Klein, Eric A.
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 559 - 566
  • [26] Hypofractionated Radiation Therapy Versus Conventional Radiation Therapy in Patients With Intermediate- to High-Risk Localized Prostate Cancer
    Guo, W.
    Gao, X. S.
    Gu, X.
    Ma, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E236 - E237
  • [27] Phase 1 Trial of Neoadjuvant Radiation Therapy Before Prostatectomy for High-Risk Prostate Cancer
    Koontz, Bridget F.
    Quaranta, Brian P.
    Pura, John A.
    Lee, W. R.
    Vujaskovic, Zeljko
    Gerber, Leah
    Haake, Michael
    Anscher, Mitchell S.
    Robertson, Cary N.
    Polascik, Thomas J.
    Moul, Judd W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (01): : 88 - 93
  • [28] Phase II Trial of Neoadjuvant Docetaxel and Gefitinib Followed by Radical Prostatectomy in Patients With High-Risk, Locally Advanced Prostate Cancer
    Vulky, Jacqueline
    Porter, Christopher
    Isacson, Christina
    Vaughan, Matthew
    Klowski, Paul
    Picozzi, Vincent
    Corman, John
    CANCER, 2009, 115 (04) : 784 - 791
  • [29] Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer
    Magnino, A
    Gatti, M
    Massucco, P
    Sperti, E
    Faggiuolo, R
    Regge, D
    Capussotti, L
    Gabriele, P
    Aglietta, M
    ONCOLOGY, 2005, 68 (4-6) : 493 - 499
  • [30] Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Risk Stratification for Intermediate- and High-Risk Patients
    Katz, A.
    Kang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E250 - E250
12345